Optimizing mRNA purification conditions by using a High Throughput Screening approach

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

To support the development of mRNA-based therapies we have developed a platform chromatography solution for the purification of mRNA. The POROS^TMOligo dT(25) affinity resin helps to address the selectivity and capacity requirements for the large-scale manufacturing of mRNA used in vaccine and gene therapy applications. The resin enables a simplified mRNA purification workflow and maximizes the removal of the DNA template and other IVT components.

Typically, mRNA binds to the Oligo dT(25) affinity resin using high ionic strength conditions and neutral pH and is eluted from the column using low ionic strength solutions like water. Although water works well for most mRNA constructs, a need to identify alternative elution buffers which can be used to optimize mRNA recovery, exists. In this webinar you will learn more on how we identified complementary elution buffers by executing a High Throughput Screening (HTS) study.

We evaluated a series of buffers at various pH levels and ionic strengths and determined the recovery. The results from this study will enable a broader understanding of steps that can be taken to optimize affinity chromatography in the mRNA manufacturing process.

Watch this webinar to:

• Find out the details of the POROS Oligo (dT)25 affinity resin and how it is used for the purification of mRNA
• Learn how to prepare and implement a HTS approach to identify alternative elution buffer conditions for the POROS Oligo(dT)25 affinity resin.
• Understand how to the ionic strength of the binding conditions can impact the recovery
• Learn how to apply the optimized purification method towards various lengths of mRNA constructs.

Jenny England

Application Scientist and Innovation Leader at Thermo Fisher Scientific

Dr. Jenny England is a Staff Scientist in the Applications and Innovation group in Purification and Pharma Analytics at Thermo Fisher Scientific. Jenny is a biophysicist by training and earned her Ph.D. from Georgetown University. After graduate school, she did a post doc at the National Cancer Institute that focused on structure-based drug design for protein kinase complexes. Jenny currently leads the application group for process development of the POROS resin products for antibody, mRNA, plasmid, and viral vector purification. Additionally, Jenny evaluates new and emerging technologies that can be applied to solve unmet customer needs in the bioproduction workflow.

Watch now

SPEAKERS

Jenny England

Application Scientist and Innovation Leader at Thermo Fisher Scientific

You might also like

Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME

Emily Neil, Ariadna Pascual

27 June

in 69

Days

Register

Pure and simple: understanding LNP analytics for better mRNA-based drugs

Adam Crowe

29 May

in 40

Days

Register

Empowering patient care: in-process and quality control solutions for cellular therapies

Christin Tischner, Simon Lennartz

23 May

in 34

Days

Register

T cells from beginning to end: optimizing leukopak and drug product cryopreservation

Meredith Safford, ShaNelle Yelity

22 May

in 33

Days

Register

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

in 32

Days

Register